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Introduction
Notch signaling is an evolutionarily conserved pathway 
that is essential for embryonic development, organo-
genesis, and tissue homeostasis. Aberrant Notch signal-
ing is associated with several inherited developmental 
diseases and various types of cancer. Th  e membrane-
anchored Notch receptor is cleaved into two fragments 
post-translationally and is assembled into the plasma 
membrane as a non-covalently linked heterodimer of the 
N-terminal and C-terminal fragments. Upon ligand 
binding, the bipartite receptor undergoes at least two 
sequential cleavages – with the last one mediated by the 
γ-secretase complex – to release the active intracellular 
domain (NICD). NICD then translocates into the nucleus 
to form a trimeric core transactivation complex with the 
sequence-speciﬁ   c DNA-binding protein, CSL (CBF-1/
Su(H)/Lag-1), and Mastermind or Mastermind-like 
protein (MAML), which further recruits other trans-
cription activators to activate the transcription of Notch 
target genes. Th   e four mammalian Notch paralogs share 
similar structural motifs and the same activation pro-
cesses and interact with the same CSL and MAML 
proteins (reviewed in [1]).
A possible link between Notch signaling and breast 
cancer was ﬁ   rst noted when a hot spot for mouse 
mammary tumor virus (MMTV) insertional mutagenesis, 
Int3, was found to be Notch4 [2]. Sequence analysis of the 
host-viral junctions revealed that all of the tumorigenic 
MMTV insertions occurred between the negative regula-
tory region (NRR) and the transmembrane domain, 
which ultimately produce high int3/Notch4 intracellular 
domain (N4ICD) levels [2]. Expression of the intracellular 
domain of int3/Notch4 speciﬁ  cally in developing secret-
ary mammary epithelium induced mammary carcinoma, 
conﬁ  rming that aberrant int3/Notch4 signaling is tumori-
genic [3]. Later, transgenic mice expressing constitutively 
active N1ICD or N3ICD in mammary epithelium were 
also shown to develop mammary gland carcinomas [4]. 
Th  ese observations, together with the report that high 
expression of Jagged1, a Notch ligand, or Notch1 (or 
both) which likely leads to elevated Notch signaling is 
associated with poor clinical outcomes [5], have stimu-
lated intense interest in exploring Notch signaling as a 
therapeutic target for breast cancer treatment (reviewed 
in [6,7]). Th   is review critically evaluates the evidence that 
supports or challenges the hypothesis that the inhibition 
of Notch signaling has therapeutic poten  tial in the 
treatment of breast cancer.
Is Notch signaling aberrantly activated in breast 
cancer?
Unlike T-cell acute lymphoblastic leukemia (T-ALL), in 
which more than half of patients have an activating 
mutation in Notch1 [8], a chromosomal translocation 
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be reported in breast cancer. In T-ALL, activating muta-
tions are commonly found in the Notch1 NRR that 
regulates NICD production and in the proline/glutamic 
acid/serine/threonine-rich (PEST) domain, which regu-
lates NICD turnover. However, among 48 breast cancer 
samples, only one nonsense mutation in Notch2, which 
produced a truncated PEST domain and potentially 
enhanced Notch2 signaling, was found [9]. No mutations 
in the other three Notch receptors were observed. 
However, as will be discussed later, the functional conse-
quence of Notch2 activation – suppressing or promoting 
breast tumorigenesis – remains to be investigated. Th  e 
absence of mutations raises the critical question of how 
Notch signaling could be activated and pathological in 
breast cancer. Two possible explanations have been 
proposed: (a) higher expression of Notch receptors or 
ligands or both and (b) loss of the negative regulator, 
Numb.
Several studies reported that the expression of Notch 
receptor and ligand proteins is higher in breast cancer 
tissues than in normal breast epithelium [10-13]. Rizzo 
and colleagues [12] examined the expression of Notch1, 
Notch4, Jagged1, and Dll1 in 4 normal breast tissues, 5 
hyperplasias of usual type (HUTs), 27 ductal carcinomas 
in situ (DCISs), 27 inﬁ  ltrating ductal carcinomas (IDCs), 
and 14 inﬁ  ltrating lobular carcinomas (ILCs) by immuno-
histochemistry. None of the normal breast tissues 
expressed high levels of Notch1 or Notch4. In contrast, 
80% of HUTs, 67% of DCISs, 89% of IDCs, and 57% of 
ILCs expressed high levels of Notch1. High Notch4 levels 
were not detected in any HUT or DCIS samples but were 
present in 81% of IDCs and 93% of ILCs. Th  e  expression 
of Jagged1 and Dll1 was not examined in normal tissues, 
HUTs, or DCISs, but 78% of IDCs and 64% of ILCs 
expressed high Jagged1 levels. Similarly, another study 
reported higher expression level of multiple Notch recep-
tors and ligands in IDC compared with normal breast 
tissues [13].
In a later study, Zardawi and colleagues [11] used tissue 
microarrays to examine Notch1 expression in 693 
samples from 222 patients. Surprisingly, although the 
authors found a gradual increase in the percentage of 
high Notch1 expression cases from normal breast tissues 
(13.6%) to grade 2 or 3 DCISs (57% to 59%), which is 
consistent with the notion that Notch1 signaling is 
activated in breast cancer and promotes tumor pro  gres-
sion, the expression level of Notch in IDCs was lower 
than that in DCISs. More surprisingly, a recent study that 
examined 79 normal breast and 408 breast cancer 
samples, including 367 IDC and 29 ILC cases, found no 
diﬀ  erence in the expression of Notch1 protein between 
breast cancer and normal breast tissues [14]. Th  erefore, 
whether expression of Notch receptors and ligands, 
especially Notch1 protein, is elevated in breast cancer 
tissues, or whether their expression level is increased 
during early stages of breast cancer development but 
declines during later stages, remains to be clariﬁ  ed.
Another proposed mechanism for aberrant Notch 
activation in breast cancer is the loss of a Notch-negative 
regulator, Numb. It is generally believed that Numb 
downregulates Notch signaling by promoting its polyubi-
quiti  nation and lysosomal degradation or by regulating 
its endocytosis (or both), consequently reducing its 
availability on the cell surface, where it responds to ligand 
binding-induced activation [15]. Numb was found to be 
absent or at low levels in approximately 50% of breast 
cancer samples and this was due to enhanced protea-
somal degradation [16]. Consistent with this, Stylianou 
and colleagues [17] detected N1ICD (the active form of 
Notch1) in 20 breast cancer samples from which Numb 
was absent. However, the correlation between Notch 
activation and loss of Numb needs to be examined in a 
larger group of patients as a recent study of 36 IDC cases 
failed to demonstrate a direct correlation [13].
It should be emphasized that, while both elevated 
expression of Notch receptors and ligands and loss of 
Numb suggest the possibility of aberrant Notch activa-
tion, they are not, per se, equivalent to enhanced Notch 
signaling, which needs to be veriﬁ  ed by the presence of 
active NICD and upregulated expression of Notch target 
genes. To this end, Mittal and colleagues [13] reported 
that both active N1ICD and Hes1/5 protein could be 
detected in 27 out of 35 IDC samples but were present in 
only 1 of 13 normal breast tissues. N1ICD was detected 
in the nucleus and cytoplasm. Since active NICD in 
cultured breast cancer cells is always present in nuclei, 
the nature of cytoplasmic N1ICD in this study needs to 
be clariﬁ  ed further, as does the speciﬁ  city of the primary 
antibody used. Furthermore, others have failed to ﬁ  nd a 
diﬀ  erence in Hes1 expression when comparing normal 
breast tissues with breast cancer tissues [18]. Th  is  raises 
concerns as to whether Notch is aberrantly activated or 
whether Hes1 is even a Notch target gene in breast 
cancer tissues.
Even if Notch signaling is more active in breast cancer 
compared with normal breast tissue, it remains to be 
determined whether the activation is suﬃ   cient to drive 
breast oncogenesis. Also, it is not known whether breast 
tumorigenesis requires the cooperation of other signaling 
pathways with Notch. Th   is might be expected given that 
several activating Notch mutant alleles commonly found 
in T-ALL cannot initiate oncogenesis alone, despite their 
ability to activate several Notch target genes [19].
Notch and breast cancer progression
Interest in exploring Notch signaling as a potential target 
for breast cancer treatment stems from early reports that 
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both, which potentially result in aberrant Notch activity, 
were correlated with poor clinical outcomes [5,10]. 
Reedijk and colleagues [5] reported that high levels of 
Jagged1, Notch1, or Notch3 mRNA were correlated with 
increased mortality in two independent cohorts of breast 
cancer samples; and the 5-year survival rates for the 
high- versus low-expression groups were 42% versus 65% 
for Jagged1, 49% versus 64% for Notch1, and 48% versus 
61% for Notch3. Later, in an expanded study that 
included 887 patients with lymph node-negative breast 
cancer, the same group found that Jagged1 expression 
still had predictive value [20]. However, a subsequent 
study that analyzed two publicly available breast cancer 
gene expression proﬁ   le datasets found that Notch1 
mRNA levels were not of prognostic signiﬁ  cance [11]. In 
addition, Notch1 protein levels were not of prognostic 
value in a cohort of 228 patients with breast cancer. 
Th   erefore, it remains to be determined whether aberrant 
Notch signaling is associated with breast cancer 
progression and clinical outcome and, if so, whether it is 
paralog-speciﬁ  c.
Jagged1 and bone metastasis
A very recent publication provides an intriguing alterna-
tive explanation of how high Jagged1 expression could be 
associated with poor clinical outcome through 
mechanisms other than activating Notch signaling and 
promoting proliferation in breast cancer cells [21]. Sethi 
and colleagues [21] observed that the expression of 
Jagged1, but not that of Notch receptors, is higher in 
high-metastatic cell lines than in their low-metastatic 
counterparts and that it positively correlated with the 
incidence of bone metastasis in patients with breast 
cancer. Knocking down or overexpressing Jagged1 in 
breast cancer cell lines inhibited or enhanced their bone 
metastatic capacity, respectively, without aﬀ  ecting  the 
growth of cultured cells or of primary mammary tumors. 
Further investigation revealed that this pro-metastasis 
function of tumor-derived Jagged1 was mediated by at 
least two mechanisms: (a) stimulating osteoblasts to 
release interleukin-6 that, in turn, promotes the growth 
of cancer cells and (b) inducing severe osteolysis by 
promoting osteocalst diﬀ   erentiation, thus providing 
space for metastatic breast cancer cells to proliferate. Th  e 
ability of MRK-003, a speciﬁ  c γ-secretase inhibitor (GSI), 
to delay the onset of bone metastasis suggests that 
blocking Notch activation in the bone marrow micro-
environment might prevent or reduce bone metastasis in 
patients with breast cancer.
Notch and subtypes of breast cancer
Since breast cancer is composed of several subtypes 
associated with distinct gene expression proﬁ  les  and 
diﬀ  erent clinical outcomes [22], it is possible that aber-
rant Notch signaling is associated with the oncogenesis 
and progression of a particular breast cancer subtype. 
Using a cohort of 611 patients with breast cancer, Dick-
son and colleagues [23] ﬁ  rst reported that high Jagged1 
mRNA levels are associated with basal-like breast cancers: 
estrogen receptor (ER)-negative and CK5-positive. 
Interestingly, they found that there was no direct 
correlation between Jagged1 mRNA and protein levels 
and that high Jagged1 protein level was associated with 
ER-positive, rather than ER-negative, patients. Similarly, 
Lee and colleagues [9] suggested that high Notch1 mRNA 
levels are associated with basal type breast cancer, but 
two other studies found that high levels of Notch1 
protein were associated with HER-2 and luminal types of 
breast cancer, respectively [11,14]. Since it is the protein, 
not the mRNA, levels of Notch receptors and ligands that 
dictate the activation status of Notch signaling, studies 
that examine protein levels should be more reliable. 
However, it should be noted that, in the study that 
suggested an association of Notch1 with HER-2 type, 
only 17 of 224 patients were classiﬁ  ed as HER-2 [11]. 
Th   erefore, the association might not hold when a larger 
group of HER-2 type patients is examined.
On the other hand, studies with established breast 
cancer cell lines have suggested that higher Notch 
activity, as measured by an RBPjκ-dependent reporter, 
was associated with HER-2-negative or ER/progesterone 
receptor (PR)/HER-2-triple-negative – commonly regarded 
as basal-like – breast cancer cell lines, although the 
diﬀ   erence between triple-negative MDA-MB-231 and 
ER/PR-positive MCF-7 was statistically signiﬁ  cant in one 
study [12] but not in the other [24]. Th  is is consistent 
with the reported high expression levels of Jagged1 and 
selective cytotoxicity of Jagged1 knockdown in triple-
negative breast cancer cell lines [25] and the selective 
cytotoxicity of Notch3 knockdown in HER-2-negative 
breast cancer cell lines [26]. However, in another study 
[21], Jagged1 knockdown did not aﬀ  ect the proliferation 
of MDA-MB-231 cells in vitro or as primary mammary 
tumors, although it did suppress bone metastasis. In 
addition, as will be described below, blocking Notch 
activation with speciﬁ  c GSIs is not selectively toxic to 
HER-2-negative or -triple-negative breast cancer cells in 
culture [27,28]. Th   erefore, these discrepancies need to be 
addressed to conﬁ   rm the association of higher Notch 
activity with HER-2-negative or -triple-negative breast 
cancers.
Functional diff  erences among Notch paralogs in 
breast cancer
Most studies, especially those examining the status of 
Notch receptors in clinical samples, have focused on the 
Notch1 paralog, although there is no evidence that other 
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cancer. It should be noted that the four Notch paralogs 
are thought to play diﬀ   erent, even opposing, roles in 
breast cancer, a fact that complicates the design of thera-
peutic strategies to block Notch signaling [10,29].
Parr and colleagues [10] reported that high Notch2 
mRNA expression levels were associated with good 
clinical outcomes, thus suggesting a tumor suppressor 
role for Notch2 in breast cancer. Th  is hypothesis was 
supported by O’Neill and colleagues [29], who showed 
that ectopic expression of active N2ICD in breast cancer 
MDA-MB-231 cells retarded cell growth and induced 
apoptosis in vitro whereas ectopic expression of N4ICD 
enhanced cellular proliferation. However, the tumor 
suppressor activity of Notch2 has been reported only in 
MDA-MB-231, a basal-like cell line. Whether it also 
holds true in a luminal type or HER-2 type of breast 
cancers (or both) remains to be investigated. Another 
group has suggested a positive correlation between 
Notch2 and HER-2 expression levels [30]. In addition, a 
positive association between Notch2 expression and a 
single-nucleotide polymorphism associated with high 
risk of breast cancer has been reported in a subset of 
patients with breast cancer (ER-positive with wild-type 
p53) [31]. Th  ese two latter observations suggest that 
Notch2 might function as an oncogene rather than as a 
tumor suppressor. It is interesting to note that, while 
transgenic mice expressing active Notch1/3/4 intra-
cellular domains have been generated and all develop 
mammary carcinoma, no transgenic mouse constitutively 
expressing active N2ICD speciﬁ   cally in mammary 
epithelium has been reported.
Dependence of breast cancer on Notch signaling
Whether Notch inhibition can be exploited to treat 
breast cancer depends on whether breast cancer cells 
require Notch signaling for their survival or malignant 
phenotype or both. Th  e most widely used approach to 
block Notch signaling in breast cancer cells, as in cells of 
other types of cancer, has been the use of GSIs. Several 
early studies reported that the GSI z-Leu-Leu-Nle-CHO, 
commonly referred as GSI I, could induce cell cycle arrest 
and apoptosis in breast cancer cells and that ER-negative 
cell lines are more sensitive [12,32,33]. However, we have 
found that the cytotoxicity of GSI I is mediated by 
proteasome inhibition rather than γ-secretase inhibition 
[27]. In addition, we found that more speciﬁ  c GSIs – 
DAPT or L-685,458 – had no signiﬁ  cant cytotoxicity in 
six breast cancer cell lines with diﬀ  erent genetic back-
grounds. Th  e lack of cytotoxicity of DAPT in breast 
cancer cells was conﬁ  rmed by a recent study [28]. While 
this is discouraging, the recent study by Dong and 
colleagues [28] demonstrated that, although treatment 
with DAPT or an epidermal growth factor receptor 
(EGFR) inhibitor, geﬁ  tinib, alone showed no cytotoxicity, 
the combination of DAPT with geﬁ  tinib induced signiﬁ  -
cant growth arrest and cell death in basal-like breast 
cancer cells. Th   e authors did not determine whether this 
combination is also eﬀ  ective in luminal and HER-2 type 
breast cancer cells.
It is important to recognize that, while these results 
suggest a clinical potential for Notch inhibition in combi-
nation therapy, there are more than 20 γ-secretase sub-
strates and many have biological functions in breast 
cancer [34]. Th   erefore, it would be useful to block Notch 
signaling by means of a more speciﬁ   c approach. For 
example, dominant negative MAML1 (dnMAML1) could 
be used in breast cancer cell lines in order to conﬁ  rm that 
Notch signaling was responsible for the observed GSI 
cytotoxicity. To this end, Meurette and colleagues [35] 
reported that DAPT sensitized ER-positive MCF-7 and 
basal-like DCIS.com cells to a DNA-damaging drug 
(melphalan), although DAPT alone was not cytotoxic. In 
that study, transient expression of Numb or dnMAML1 
was also used, with similar eﬀ  ects, to downregulate Notch 
activity. Since Notch inhibition has also been reported to 
sensitize breast cancer cells to tamoxifen and trastuzumab 
[12,24], Notch inhibition in combination with other drugs 
holds a promising future in breast cancer management. Its 
potential as a monotherapy is more doubtful.
In contrast to reports that GSI treatment alone did not 
induce signiﬁ   cant cytotoxicity in breast cancer cells, 
several studies reported that knocking down individual 
Notch paralogs by short interfering RNA (siRNA) was 
cytotoxic. Yamaguchi and colleagues [26] found that, 
although Notch1 knockdown had only a slight eﬀ  ect, 
Notch3 knockdown signiﬁ  cantly impaired the growth of 
HER-2/neu-negative, but not -positive, cells. However, 
others have shown that knockdown of Notch1 by siRNA 
inhibits breast cancer cell growth [12,24,36]. Since the 
speciﬁ  city of siRNA has always been a concern in knock-
down experiments, it would be more convincing if the 
cytotoxicity could be reversed by expression of siRNA-
resistant full-length Notch receptors. It is critical, how-
ever, that full-length rather than simply the NICD 
constructs be used. It has been reported that N1ICD 
showed a dose-dependent eﬀ   ect on the phenotypic 
response in mammary epithelial MCF-10A cells [37], and 
overexpression of N1ICD has been shown to protect a 
number of cancer cell lines from several chemotherapy 
drugs [38]. Unlike full-length Notch proteins, NICD 
fragments will constitutively activate the Notch pathway 
and are likely to accumulate in vast excess of what would 
be generated by cleavage of endogenous Notch or a 
transfected full-length Notch construct. Th  erefore, the 
phenotype reversion arising from expression of NICD 
could be the result of overexpression rather than restora-
tion of NICD.
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individual Notch paralogs could be tested using well-
characterized, paralog-speciﬁ   c antagonizing antibodies 
that have recently been developed [39,40]. If down  regu-
lating the activity of individual Notch paralogs indeed 
induces cell growth arrest or cell death (despite the lack 
of signiﬁ  cant cytotoxicity associated with treatment with 
GSI alone), this would suggest that other γ-secretase 
substrates function antagonistically to the pro-survival 
Notch signaling. Determining whether this is the case is 
essential to the development of eﬀ  ective  therapeutic 
approaches to block oncogenic Notch signaling in the 
treatment of breast cancer.
Notch and breast cancer stem cells
Another motivation for exploring Notch inhibition for 
breast cancer treatment is that Notch signaling has been 
proposed to maintain the stemness of breast cancer stem 
cells (CSCs). Farnie and colleagues [41] examined the 
factors that aﬀ  ect the ability of breast cancer cells to form 
mammospheres, an indicator of stemness of breast CSCs. 
Th  e authors found that DAPT treatment reduced the 
mammosphere-forming eﬃ     ciency (MFE) of primary 
breast cancer cells. Furthermore, treatment with a poly-
clonal Notch4 neutralizing antibody reduced MFE to a 
greater extent than did DAPT treatment, suggesting that 
Notch4 signaling was involved in maintaining breast CSC 
stemness. Consistent with this, Harrison and colleagues 
[42] reported that Notch4, but not Notch1, signaling is 
important for regulating breast CSC activity. N1ICD 
levels were lower and N4ICD levels were higher in the 
CSC subpopulation compared with the non-CSC sub-
popu  lations. In addition, Notch4 knockdown produced a 
greater reduction in the MFE and tumorigenic potential 
in xenografts than did Notch1 knockdown in MCF-7 
cells. However, the antibodies used do not speciﬁ  cally 
recognize the active NICD; more importantly, treatment 
with GSIs reduced the signal of ‘N1ICD’, but not that of 
‘N4ICD’, as determined by immunoblotting in both 
MCF-7 and MDA-MB-231 cells. Since cleavage of int3/
Notch4 has been previously reported to be sensitive to 
GSI treatment [43,44], this raises concerns over the 
speciﬁ  city of the anti-Notch4 antibody and, consequently, 
the validity of these observations. Finally, it should be 
noted that DAPT treatment reduced the MFE by only 
20%. If blocking Notch4 signaling is more eﬀ  ective in 
abrogating the stemness of breast CSCs than DAPT 
treatment, then some unidentiﬁ  ed γ-secretase substrates 
must antagonize Notch4 activity.
Targeting RBPjκ-independent Notch signaling
In addition to the CSL-dependent canonical Notch 
signal  ing described above, CSL-independent Notch 
activi  ties have been reported, although most of the 
underlying molecular mechanisms are not well under-
stood (reviewed in [45]). One of the best-characterized 
mechanisms is N1ICD inhibition of myogenesis by its 
competition with MEF2C for MAML1, the transcrip-
tional activator required for myogenesis [46]. Th  e other 
possible mechanisms underlying CSL-independent Notch 
activities include the formation of novel NICD-
containing protein complexes. It has been reported that 
NICD could associate with NFκB, IKKα, Smad3, HIF-1α, 
YY1, and JNK, although the conditions for these associa-
tions have not been well characterized [45,47,48].
Th   e relative contributions of CSL-dependent canonical 
and CSL-independent non-canonical Notch activities to 
Notch-induced tumorigenesis have not been extensively 
investigated, although early studies suggested that non-
canonical Notch activities might be involved [49]. A 
compelling study by Raafat and colleagues [50] demon-
strated that active N4ICD can induce mammary gland 
carcinoma in the absence of RBPjκ, the murine ortholog 
of the sequence-speciﬁ   c DNA-binding protein CSL. 
What mediates RBPjκ-independent oncogenic Notch4 
signaling remains to be determined, as does whether the 
RBPjκ-independent tumorigenic activity described for 
Notch4 is a property that applies to other Notch paralogs. 
Nonetheless, this unexpected observation raises an 
intriguing question: can Notch-dependent cancer cells be 
killed by targeting RBPjκ-independent Notch signaling?
When we expressed diﬀ   erent levels of Flag-tagged 
N1ICD in MCF-7 cells, we found by co-immunoprecipi-
tation that the amount of canonical N1ICD/RBPjκ/
MAML protein complex became proportionally less with 
increasing levels of N1ICD [51]. Further investigation by 
examining the molecular weight distributions of RBPjκ 
and three MAML homologs while increasing the 
expression of Flag-N1ICD revealed that MAML proteins 
are the limiting factor for continuous formation of 
canonical NICD/RBPjκ/MAML protein complex. As the 
N1ICD expression increased, the co-elution of N1ICD 
and MAML decreased. On the basis of this, we propose 
that active NICD could function through three 
mechanisms: (a) activation of direct Notch target genes 
by the NICD/RBPjκ/MAML transactivation complex, (b) 
competing MAML (or RBPjκ away from other interacting 
proteins, thus inhibiting their activities), and (c) 
introducing new signaling pathways through the 
formation of novel NICD complexes (Figure 1). Th  e  third 
mechanism may be responsible for oncogenic Notch4 
signaling in the absence of RBPjκ but all Notch paralogs 
are expected to have this potential. It is possible that the 
activation of novel signaling pathways may arise only 
after NICD saturates MAML proteins. Th   is is more likely 
to occur in cancer cells, in which Notch is aberrantly 
activated, as opposed to normal cells, in which Notch 
activation is tightly regulated. If this hypothesis is correct, 
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safe but eﬀ   ective approach to block oncogenic Notch 
activity while preserving the physiological activities of 
Notch which may be important for normal tissue 
functioning.
Th   ere are several indirect lines of evidence that support 
our hypothesis: (a) the dose-dependent nature of the 
trans  formation potential of activating Notch1 mutant 
alleles in T-ALL might reﬂ  ect the fact that the N1ICD 
level needs to reach a threshold above which N1ICD 
could activate several non-canonical Notch signaling 
pathways by forming novel NICD protein complexes; (b) 
NICDs have been reported to associate with NFκB, IKKα, 
Smad3, HIF1α, YY1, and JNK, all of which have been 
implicated in oncogenesis and cancer cell survival 
[45,47,48]; and (c) inhibition of NFκB activity delayed the 
onset of N1ICD-induced oncogenesis of T-ALL [52]. 
Th   erefore, a better understanding of the components of 
RBPjκ-independent oncogenic Notch signaling pathways 
and their contribution to Notch-induced tumorigenesis 
would help us to develop new strategies to treat Notch-
dependent cancers.
Conclusions
Notch signaling is attractive as a potential therapeutic 
target for breast cancer management. However, after 
years of intensive investigation, there are still many 
uncertainties that prevent the successful exploitation of 
this target. To a large degree, these discrepancies arise 
from the complex nature of the Notch signaling pathway 
as well from limitations of existing reagents. We believe 
that it is essential to develop well-characterized and 
highly speciﬁ  c antibodies that can be used to directly and 
quantitatively detect the activation status of individual 
Notch paralogs in diﬀ  erent types of breast cancers. In 
addition, since there are several approaches – speciﬁ  c 
GSIs, dnMAML1, and inhibitory antibodies – available 
to block Notch signaling, it is important to employ more 
than one approach when investigating the biological 
outcomes of Notch inhibition. More emphasis should 
also be placed on speciﬁ  city rather than eﬃ   cacy if we are 
to improve upon the current therapeutic use of GSIs. 
Finally, it will be important to investigate the contribu-
tions of non-canonical Notch activities to the onco-
genesis and cell survival of Notch-dependent breast 
Figure 1. Model for activation of multiple Notch signaling pathways. In the absence of Notch activity (that is, no NICD) (left), RBPjκ associates 
with transcription repressors to suppress the expression of canonical Notch target genes. Upon Notch activation under physiological conditions 
in which the NICD level is low (middle), NICD is assembled predominantly into the canonical NICD/RBPjκ/MAML complex that will activate the 
canonical Notch signaling pathway as well as aff  ect the activity of other MAML- or even RBPjκ-interacting proteins by depriving them of MAML or 
RBPjκ. This is a result of the higher affi   nity of the NICD/RBPjκ/MAML complex compared with the non-canonical complexes. Upon aberrant Notch 
activation under oncogenic conditions (right) in which high levels of NICD saturate available MAML proteins, the affi   nity of NICD/RBPjκ dimer is not 
suffi   cient to prevent the formation of non-canonical NICD complexes. Consequently, a fraction of NICD will associate with other proteins such as 
NFκB and Smad3 as shown. With further increase in the NICD levels, other non-canonical NICD complexes will form in an ordered manner on the 
basis of their relative affi   nities and abundance. Each individual non-canonical NICD-containing protein complex will activate a signaling pathway 
(not necessarily a transcription-based pathway, which is shown) and the resulting cellular phenotype will refl  ect the combination of multiple 
signaling pathways. In this model, removing RBPjκ from cells will force the formation of non-canonical NICD complexes such as have been reported 
to be responsible for RBPjκ-independent Notch4 oncogenic activity. MAML, Mastermind-like protein; NFκB, nuclear factor-kappa-B; NICD, Notch 
intracellular domain.
Han et al. Breast Cancer Research 2011, 13:210 
http://breast-cancer-research.com/content/13/3/210
Page 6 of 8cancers. A better understanding of non-canonical Notch 
activities may lead to development of therapeutic 
strategies that minimize harm in normal tissue while 
eﬀ  ectively inhibiting the oncogenic Notch signaling.
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